Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 23323618)

1.

Searching for phytoinsulins as cardiovascular protector in metabolic syndrome.

Ji L, Xing W, Dong L, Gao F.

Curr Pharm Des. 2013;19(27):4848-58. Review.

PMID:
23323618
2.

Role of habitual physical activity in modulating vascular actions of insulin.

Padilla J, Olver TD, Thyfault JP, Fadel PJ.

Exp Physiol. 2015 Jul 1;100(7):759-71. doi: 10.1113/EP085107.

PMID:
26130183
3.

Cardiovascular disease: Insulin sensitizer protects the heart.

Crunkhorn S.

Nat Rev Drug Discov. 2015 Feb;14(2):93. doi: 10.1038/nrd4540. No abstract available.

PMID:
25633791
4.

A Review of the Benefits of Satureja Species on Metabolic Syndrome and Their Possible Mechanisms of Action.

Babajafari S, Nikaein F, Mazloomi SM, Zibaeenejad MJ, Zargaran A.

J Evid Based Complementary Altern Med. 2015 Jul;20(3):212-223. Epub 2015 Jan 5. Review.

PMID:
25563729
5.

All in the family: Clueing into the link between metabolic syndrome and hematologic malignancies.

Karmali R, Dalovisio A, Borgia JA, Venugopal P, Kim BW, Grant-Szymanski K, Hari P, Lazarus H.

Blood Rev. 2015 Mar;29(2):71-80. doi: 10.1016/j.blre.2014.09.010. Epub 2014 Sep 28.

PMID:
25433571
6.

Adiponectin signaling and metabolic syndrome.

Fu Y.

Prog Mol Biol Transl Sci. 2014;121:293-319. doi: 10.1016/B978-0-12-800101-1.00009-0. Review.

PMID:
24373241
7.

Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms.

Guo S.

J Endocrinol. 2014 Jan 8;220(2):T1-T23. doi: 10.1530/JOE-13-0327. Print 2014 Feb. Review.

8.

Metabolic syndrome and cardiovascular health: a look beyond the horizon.

Zhang Y, Ren J.

Curr Pharm Des. 2013;19(27):4797-8. No abstract available.

PMID:
23844872
9.

[The role of adiponectin in the pathogenesis of the metabolic syndrome and approach to therapy].

Rodina AV, Severin SE.

Patol Fiziol Eksp Ter. 2013 Jan-Mar;(1):15-26. Review. Russian.

PMID:
23805709
10.

Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.

Defronzo RA, Mehta RJ, Schnure JJ.

Hosp Pract (1995). 2013 Apr;41(2):132-47. doi: 10.3810/hp.2013.04.1062.

PMID:
23680744
12.

Roles of p38-MAPK in insulin resistant heart: evidence from bench to future bedside application.

Kumphune S, Chattipakorn S, Chattipakorn N.

Curr Pharm Des. 2013;19(32):5742-54. Review.

PMID:
23448488
13.

Pharmacological approach to cardiovascular risk in metabolic syndrome.

Bellis A, Trimarco B.

J Cardiovasc Med (Hagerstown). 2013 Jun;14(6):403-9. doi: 10.2459/JCM.0b013e32835dbd0d. Review.

PMID:
23337396
14.

Role of insulin resistance in endothelial dysfunction.

Muniyappa R, Sowers JR.

Rev Endocr Metab Disord. 2013 Mar;14(1):5-12. doi: 10.1007/s11154-012-9229-1. Review.

15.

A review of the cardiovascular and anti-atherogenic effects of ghrelin.

Rizzo M, Rizvi AA, Sudar E, Soskic S, Obradovic M, Montalto G, Boutjdir M, Mikhailidis DP, Isenovic ER.

Curr Pharm Des. 2013;19(27):4953-63. Review.

PMID:
23278489
16.

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Nov 14;11:140. doi: 10.1186/1475-2840-11-140. Review.

17.

Insulin sensitization via partial agonism of PPARĪ³ and glucose uptake through translocation and activation of GLUT4 in PI3K/p-Akt signaling pathway by embelin in type 2 diabetic rats.

Gandhi GR, Stalin A, Balakrishna K, Ignacimuthu S, Paulraj MG, Vishal R.

Biochim Biophys Acta. 2013 Jan;1830(1):2243-55. doi: 10.1016/j.bbagen.2012.10.016. Epub 2012 Oct 24.

PMID:
23104384
18.

Metformin alters the insulin signaling pathway in ischemic cardiac tissue in a swine model of metabolic syndrome.

Elmadhun NY, Lassaletta AD, Chu LM, Sellke FW.

J Thorac Cardiovasc Surg. 2013 Jan;145(1):258-65; discussion 265-6. doi: 10.1016/j.jtcvs.2012.09.028. Epub 2012 Oct 22.

19.

Treatment strategy for type 2 diabetes from the perspective of systemic vascular protection and insulin resistance.

Utsunomiya K.

Vasc Health Risk Manag. 2012;8:429-36. doi: 10.2147/VHRM.S32357. Epub 2012 Jul 4. Review.

20.

Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular disease.

Rask-Madsen C, Kahn CR.

Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2052-9. doi: 10.1161/ATVBAHA.111.241919. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk